You are here:
Ifosfamide: review of encephalopathy risk
2021.04.23
Active substance: ifosfamide
23.04.2021 - CMDh position
Benefits of ifosfamide solutions continue to outweigh risks
The CMDh, having considered the PRAC assessment report and recommendation, agreed by majority that the benefits of ifosfamide solutions for infusion continue to outweigh their risks in the treatment of different types of cancers, including various solid tumours and blood cancers such as lymphomas (cancer of white blood cells).
12.03.2021 - PRAC recommendation
Benefits of ifosfamide solutions continue to outweigh risks
EMA’s safety committee (PRAC) has concluded that the benefits of ifosfamide solutions for infusion continue to outweigh their risks in the treatment of different types of cancers, including various solid tumours and blood cancers such as lymphomas (cancer of white blood cells)
13.03.2020 - Procedure started
The EMA has initiated a risk assessment procedure on some ifosfamide-containing drugs to investigate the risk of developing encephalopathy (brain disease).
Further information
For details on the procedure please click on the following link to the homepage of the European Medicines Agency (EMA):